Rafael (RFL) News
NYSE: RFLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
0.9197+0.0197 (+2.19%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RFL news summary
We found 8 recent headlines mentioning Rafael (RFL): 0 in the past week and 8 in the past 30 days, most often from PR Newswire, GlobeNewswire, Nasdaq. For price context, RFL is up 2.19% at $0.9197. The most recent story, "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL", was published by PR Newswire on Nov 12, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Rafael headlines
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFLNEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or the "Company") (NYSE: RFL). Such investors are advised to…PR Newswire
- Rafael Holdings, Inc. Submits NDA for Remibetadex Following Phase 3 TransportNPC StudyRafael Holdings, Inc. reported that it submitted a New Drug Application (NDA) in October 2026 for remibetadex, its lead asset for the treatment of Niemann-Pick disease type C (NPC). The submission…NasdaqRFL, BF.A
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFLNEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or the "Company") (NYSE: RFL). Such investors are advised to…PR Newswire
- Rafael Holdings to Participate in the Guggenheim 3rd Annual Healthcare Innovation ConferenceNEWARK, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced that it will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation…GlobeNewswire
- Rafael Holdings Announces NDA Submission for Remibetadex and Reports Fiscal Year 2026 Financial ResultsRafael Holdings, Inc. announced that its subsidiary, Cyclo Therapeutics, LLC, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of remibetadex…Nasdaq
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFLNEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or the "Company") (NYSE: RFL). Such investors are advised to…PR Newswire
- Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate UpdateNEWARK, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the fourth quarter and full fiscal year 2026 ended July 31, 2026.GlobeNewswire
- Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type CNDA supported by the Phase 3 TransportNPC ™ study, data from earlier clinical studies, and an overall survival analysis versus external registry controlsGlobeNewswire